Cancer is a worldwide public health concern. Identifying carogens and limiting their exposure i one approach to A useful new tool which has emerged from developments in molecular biology is the transgenic rodent. Such animals have modified genes that cause them to respond to carcinogens in advantageous ways. This paper describes the response characteristics of two of the most promising of these transgenics, p53+/ and TG.AC, and discusses ways in which they may be used to improve carcinogen bioassay.
The p53+/-line responds rapidly to genotoxic carcinogens, and the TG.AC line responds rapidly to nongenotoxic carcinogens. Positive results in either could lead to an NTP bioassay modified to focus on low-level dose response; verification of carcinogenicity could be substantially accomplished by the transgenic assay, and the transgenic assay could provide guidance for dose selection. Thus, the use of these two transgenic models could accomplish several important objectives: 1) accelerated testing of environmental chemicals; 2) prioritization of chemicals for NTP bioassay; and 3) focusing the NTP bioassay on one primary objective, low-level dose response, instead of the dual objective of determining whether an agent is carcinogenic, which requires administration of high doses, and at the same time trying to determine dose-response characteristics at low doses. Conversely, as experience is accrued in the use of these transgenics, it may become evident that with agents that are clearly positive with structural alert evaluations, in vitro mutagenicity, and transgenic bioassays, the full NTP bioassay is not needed.
Transgenic Mouse Models
Appropriate transgenic mouse lines offer the opportunity to develop relatively shortterm in vivo models to identify potential carcinogens and other toxic agents. Such models include transgenic mice carrying reporter genes that may serve as targets for mutagenic events (1,2) or mice carrying specific oncogenes or inactivated tumorsuppressor genes that are important factors contributing to the multistage process of carcinogenesis (3) (4) (5) . Mouse lines with defined genetic alterations that result in overexpression or inactivation of a gene intrinsic to carcinogenesis, but that are insufficient alone for neoplastic conversion, are promising models for chemical carcinogen identification and evaluation. Likely gene targets for alteration that might result in this phenotype are 1) the activation (by mutation) of the c-Ha-ras protooncogene, which alters signal transduction and growth control (6), and 2) inactivation of the p53 tumor-suppressor gene, which is critical to cell cycle control and DNA repair (7) (8) (9) . These tumor genes are often mutated and/or amplified (c-Ha-ras) or mutated and/or lost (p53) in human and rodent tumors (10) (11) (12) (13) .
p53 +/-mice. Mice with only a single wild-type p53 allele provide a distinct target for mutagens and are analogous to humans at risk due to heritable forms of Articles -Identification of carcinogens in transgenic mice cancer, such as the Li-Fraumeni syndrome (14) . The reduction in p53 gene dosage by this "germline first hit" increases the probability that a second mutagenic event will cause either loss of p53 tumor-suppressor function or gain of transforming activity by requiring (at minimum) only a single mutation (10) (11) (12) (13) . Mice with inactive p53 genes are viable and, in the hemizygous state, have a low background tumor incidence for up to 12 months of age, whereas nullizygous mice have a higher rate of spontaneous tumors at sites apparently determined by the strain's genetic background (15, 16) .
We conducted concurrent 6-month carcinogenesis studies using male and female C57BL/6 mice hemizygous for the wildtype p53 gene together with their homozygous wild-type p53 siblings. We used two carcinogens that exhibited trans-species carcinogenicity (17) (i.e., induced tumors in both mice and rats), in long-term rodent bioassays and that were positive in the Salmonella mutagenesis assay (18) (19) (20) : p cresidine (21) and 4-vinyl-i-cyclohexene diepoxide (VCD) (22) . For comparison, we used two nonmutagenic carcinogens that were carcinogenic in only one of two test species: N-methylolacrylamide (NMOA) (23) and reserpine (24) . As a negative control, we used p-anisidine (25) , an analogue of p-cresidine, which was positive in the Salmonella assay and negative in rats and mice in two-year carcinogenesis studies. These chemicals represent the opposite ends of the spectrum of biological activity observed in rodent bioassays (18) (19) (20) . To facilitate this comparison, we used the same exposure conditions and chemical doses as used in the 2-year bioassays.
TG.AC mice. TGAC mice carry a vHa-ras oncogene fused to the promoter of the 4-globin gene (26) . The v-Ha-ras transgene has point mutations at codons 12 and 59, and the site of integration of the transgene confers on these mice the characteristic of genetically initiated skin as a target for tumorigenesis in the context of the intensively studied mouse-skin tumorigenesis model (27) . An important consideration of the TG.AC mouse model is that the transgene is not constitutively expressed in the skin, and the untreated skin appears normal when compared to the skin of the wild-type FVB/N parent strain (26, 28) . In addition, the spontaneous incidence of skin papillomas in the dorsal skin of untreated mice is very low to zero. Heterozygous or homozygous TG.AC mice receiving repetitive topical treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) or other well-described mouse-skin promoters (benzoyl peroxide, mezerein, or methyl ethyl ketone peroxide) readily develop, as early as 4-6 weeks after treatment, benign squamous papillomas which may progress to malignancy (26, 29) .
Our approach to evaluating and using the TG.AC mice is different from that for the p53+/-mice. Many of the chemicals tested initially in TG.AC were used to characterize the phenotype of the line rather than to directly assess its use in identifying carcinogens. As the studies progressed, the potential use of this line to identify putative nongenotoxic carcinogens and to permit extended dose-response analyses became apparent.
The activities of 20 chemicals have been evaluated in homozygous female TG.AC mice using a skin-painting protocol. These chemicals represent well-known mouse skin initiators and promoters (26, 29) (Table 1) . Tumors were grossly observed as thickened bladder walls or large masses, which frequently were associated with hydronephrosis due to bladder occlusion. These characteristics were similar to the tumors induced in the B6C3F1 mice used in the 2-year bioassay. Microscopically, the carcinomas were invasive masses composed of markedly anaplastic cells and/or cells exhibiting squamous differentiation. In one high-dose p53 +/-female, a squamous papilloma of the bladder mucosa was observed. Deaths related to tumor induction that occurred during the study (Table 2) were especially frequent in male mice hemizygous for wild-type p53.
p-Anisidine, an analogue ofp-cresidine, was mutagenic in the Salmonella assay and was not carcinogenic to male or female F344 rats or B6C3F1 mice in 2-year dosedfeed studies (25) . In those studies, the dose levels used induced body weight depression without an increase in mortality in the treated groups relative to the controls. In the present dosed-feed study, p-anisidine (administered equimolar to p-cresidine) did not induce any significant clinical observations or depressed body weight gain relative to the control groups (Tables 1 and 2 ). However, 5 of 15 low-dose p53 +/-mice died of unexplained causes during the study. None of the high-dose p53 +/-mice were affected. No gross lesions or microscopic lesions in the urinary bladder were observed after 24 weeks of dietary administration and a 6-week holding period. NMOA was nonmutagenic in the Salmonella assay, although it contains a chemical structural alert indicating electrophilic potential and was carcinogenic to mice in 2-year bioassays when administered by oral intubation (18, 23) (Table 1 ). In the 2-year bioassays, NMOA-treated B6C3F1 male and female mice exhibited an increase in body weight gain relative to controls and increased incidences of tumors in the Harderian gland, liver, lung, and ovary. In the studies with transgenic mice, NMOA depressed body weight gain in male mice (greatest in high-dose, wild-type siblings) and slightly increased body weight gain in female mice (data not shown). Mortality was slightly increased in high-dose male and female mice hemizygous for p53, but no induced tumors were observed (Table 2) .
Reserpine was not mutagenic in the Salmonella assay, but in the 2-year dosed feed studies, it induced mammary gland tumors in B6C3F1 female mice (18, 24) (Table 1 ). In these transgenic mouse studies, reserpine administered at 0.001% of the diet to p53 +/-mice resulted in lethargy, tremors, piloerection, and severe weight loss and death ( cDue to excessive weight loss and mortality in the high dose group, survivors were converted to the low dose feed concentration after 4 weeks of treatment and maintained in the same cages for the remainder of the study without further loss. Data were also maintained separately because of sustained body weight depression and clinical observations. hData from a collaborative study with R. Smart, North Carolina State University.
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incidence of 3 papillomas/mouse ( organ sites, in the hemizygous p53 mice as they did in B6C3F1 mice in the 2-year bioassays with the mutagenic carcinogens. These limited data suggest that the hemizygous p53 mice may exhibit a specificity of response for mutagenic carcinogens as well as increased sensitivity when compared to their normal, wild-type littermates. However, neither of the nonmutagenic carcinogens induced tumors in their expected target tissues in either hemizygous p53 or homozygous wild-type sibling mice when administered for 6 months by the same route used in 2-year bioassays. These shortterm bioassay results are consistent with the 2-year NTP bioassays for the mutagenic carcinogens, indicating that the C57BL/6 strain responded similarly to the B6C3F1 hybrid. Although the number of mice used in these studies was small compared to long-term toxicology studies, these data indicate that these mice may have increased susceptibility to mutagenic carcinogens (15, 16, 32) and that mutagenic chemicals are required to initiate the carcinogenic responses observed.
The skin-paint studies in the TG.AC transgenic mice indicate that the model can complement the standard NTP 13-week subchronic bioassays that are used to identify potential target organ sites for toxic effects or neoplasia in the 2-year bioassay. Furthermore, the model is sensitive to chemicals that do not necessarily target the skin when administered by other routes of exposure. Some major advantages of this model are that the skin-tumor response can be visibly observed and induced within a 20-week dosing regimen; furthermore, the dosing protocol (e.g., dose frequency per week) can be varied according to the toxicity of the chemical. The target organ site, the dorsal skin, is normal until stimulated by a series of chemically induced events that lead to the induction of skin papillomas (26,29l . The latency period is short, with the first tumors appearing as early as 5 weeks and usually by 10 weeks when using a 20-week dosing protocol. Further, in every instance where the treated mice were observed an additional 10-20 weeks after cessation of dosing, a subpopulation of the papillomas progressed to malignancy. Other important considerations are that the life span of homozygous TG.AC mice is well over a year, and the sporadic papilloma incidence at the target site, dorsal skin, is very low to zero in untreated or vehicle-control mice. Untreated TG.AC mouse skin has normal morphological and physiological characteristics that are maintained throughout the mouse's life span. The transgene is not constitutively expressed at the target sites, but is expressed in association with the proliferative cell component observed in early papillomas (28) . From these limited data, the TG.AC mouse model appears to identify genotoxic and nongenotoxic carcinogens and to discriminate a high proportion of carcinogens and noncarcinogens.
Dose and Dose-Rate Studies
Another potential advantage of the transgenic models is their capability of providing dosimetric data. A major controversy in toxicology is the nature of the dose response derived from rodent bioassays. Due to the variable potency and toxicity of chemicals and the variable and often high rate of site-specific sporadic tumors (50), few bioassays produce data that can be appropriately evaluated at relatively low doses. For example, benzene induced a broad spectrum of tumors in a relatively high proportion of mice in the rodent bioassay (33, 35) . When all significant sites of tumorigenesis were combined, even the low dose (20 mg/kg body weight) induced tumors in approximately 60% of male and female B6C3F1 mice. As shown in Figure   1 , these results suggest that the response at all doses could represent the upper portion of a dose-response curve, and the pattern was similar for papillomas induced by benzene in TG.AC mice. However, the prospects that lower doses in B6C3F1 mice could produce data sufficient to allow the true shape of the dose response to be deter- CLED, lowest effective dose that induced papillomas at the site of application or highest "no effect" dose administered.
dTTFP, time (weeks) to first observation of a skin papilloma in any mouse of that dose group. eAt 20 weeks.
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Articles -Identification of carcinogens in transgenic mice mined, even by extrapolation, is quite unlikely because of the high proportion of control mice that developed tumors at many of the same sites as the benzeneexposed mice by the end of the 104 week study. Because the frequency of spontaneous tumors increases with time, the distinction between induced and spontaneous tumors becomes more difficult to discern. The principal attribute of the two transgenic mouse lines described here is that induced tumors develop within a time frame in which the spontaneous tumor incidence is effectively zero, thus reducing the confounding effects observed in an aging population.
The benzene study was repeated in TG.AC mice using doses as low as 75 pl/week/mouse. The high dose portion of the dose-response pattern, similar to that for the bioassay, was observed again, but it is noteworthy that the response curve also extended into the low-dose range (Fig. 2) . These results suggest that it will be possible to compare the dose response of various chemicals, including known human carcinogens, and to study dose-rate effects of chemicals, including time-to-tumor analysis, which are critical (51) . Further, in the case of the p53 +/-mouse line, it is possible to design molecular dosimetry studies because mutational spectra of the single functional wild-type p53 alleles may be determined (12) .
Identification of Presumptive Carcinogens
Although large numbers of new chemicals are continually being synthesized for potential use, they need not all be subjected to a complete rodent bioassay. Over the past three decades, information has been developed in the characterization of the biological effects of most major structural classes of chemicals. It is possible to use available data to predict the relative toxicity or carcinogenicity of many untested chemicals.
The most predictive mechanistic determinant for chemical carcinogenicity is mutagenic potential (52) . It has been recognized for many years that chemicals that demonstrate mutagenicity in vitro are also carcinogenic to rodents (34, 53 ). An extensive evaluation of the association between mutagenicity and carcinogenicity of 114 chemicals that were subjected to rodent carcinogenicity bioassays showed that approximately 70% of the chemicals that were mutagenic in the Ames Salmonella mutagenicity assay were rodent carcinogens (53, 54) . Based on this relationship, mutagenicity, as well as other information relating to chemical structure and toxicity, were used to predict carcinogenic potential in two rodent species (55) . Forty-four chemicals that were undergoing bioassays, for which the results were not yet available, were the focus of an effort to demonstrate that chemical structure, mutagenicity, and data from subchronic toxicity studies were sufficient to prospectively identify many potential carcinogens with a high degree of certainty. The principal results of the effort showed that a chemical of unknown carcinogenicity could be predicted to be in one of three possible categories: probably carcinogenic, probably noncarcinogenic, or of uncertain activity (56) . All of the chemicals that induced trans-species carcinogenic effects were correctly predicted. Trans- Dose (Ai) species rodent carcinogens demonstrate similar properties (mutagenicity and toxicity) of proven human carcinogens and represent a more proximate risk to human health than species-restricted carcinogens (17) . The overall specific predictions were 75% concordant with the results of the rodent bioassays; the least success occurred with the chemicals that produced uncertain effects in the bioassay (i.e., equivocal evidence of carcinogenicity or single-site, sexspecific, and species-specific effects). Integration of data on chemical structure, mutagenicity, and systemic toxicity tended to overpredict carcinogenicity (i.e., 7 of 10 missed predictions were for carcinogenicity) (56) , but any predictive strategy should be risk-adverse, that is, involve principally false-positive errors (57) (58) (59) (60) .
It also became clear from this exercise that while mutagenicity is a major mechanistic determinant, this property is neither sufficient nor necessary for carcinogenicity. Approximately one-third of the nonmutagenic chemicals tested in bioassays have shown some evidence of carcinogenicity.
Conversely, approximately one-third of the chemicals that were mutagenic in vitro were not carcinogenic in the bioassay (52, 54) . Thus, mechanism-based predictions were the most accurate for potent carcinogens and for chemicals that were clearly noncarcinogens. Use of this information alone could reduce significantly the dependence on rodent bioassays. However, if further improvements in the prediction process can be achieved, it should be possi- Total benzene dose RI/w.eek Based on the responses of the p53 +/-and TG.AC mouse lines to specific chemical treatment regimens discussed here, we propose that these lines can be used selectively in conjunction with the 2-year bioassay to confirm predictions based on the aggregate of structure-activity relationships, in vitro genotoxicity, and systemic toxicity, ultimately reducing the number of chemicals (and mice) that must be subjected to 2-year rodent bioassays. The strategy is depicted in the decision-tree scheme outlined in Figure 3 ; a key element is the use of p53 +/-mice for the verification of predicted mutagenic carcinogens.
Few studies have specifically investigated the effects of environmental chemicals on the p53 tumor-suppressor gene in wildtype or genetically altered mice (16, 29, 61, 62) (/7,17,63,64) . Interaction of mutagenic carcinogens with highly conserved genes in the genome may explain, at least partly, why hemizygous p53 mice exhibit a shortened latency while retaining tissue specificity. In addition, genomic stability may decrease with loss of both wild-type p53 alleles (7, 63, 64) , possibly because of the loss of the ability to arrest the cell cycle to allow sufficient time for DNA repair and/or to induce apoptosis (8, 65, 66) .
Although the number of chemicals evaluated in the p53 +/-line are limited, the results to date support further evaluation of the proposal of using this line to identify or verify mutagenic carcinogens.
Because of the relatively rapid induction of tumors and the high proportion of the mice responding, we propose that chemicals with properties that predict mutagenicity and carcinogenicity be tested in this model before conducting a 2-year bioassay. Data relevant to potential target tissues and dose-response patterns can be obtained from a transgenic mouse study that can be conducted within 6-month exposure periods. The uniform sensitivity of the animals allows fewer mice to be used per dose group, and the absence of spontaneous tumors allows for a more categorical determination of carcinogenic potential at lower Toxicity, in general, as indicated by the empirically determined maximum tolerated dose, increases for mutagenic carcinogens compared to nonmutagenic carcinogens (17 (61,6$) .
Volume 103, Number 10, October 1995-* Environmental Health PerspectivesArticles * Identification of carcinogens in trans-enic mice Validation of this strategy can be accomplished by two approaches: one is retrospective, the other prospective. The retrospective approach, taken in the validation of in vitro or short-term test methods, has typically involved testing well-defined carcinogens. This approach led to overconfidence in the value of many short-term assays which, when they were more fully characterized for response to noncarcinogens, were found to lack sufficient specificity to be useful (52, 53) . While the selective testing of known carcinogens and noncarcinogens in the TG.AC and p53 +/-mouse lines is necessary, there is also the opportunity for a more direct and objective validation. This prospective approach involves testing chemicals that are currently undergoing long-term bioassays. By providing results, both qualitative and quantitative, before the outcome of the 2-year bioassay is known, even implicit investigator bias (such as in the selection of chemicals) is eliminated. We have implemented this approach with the TG.AC mouse line by prospectively testing four chemicals undergoing 2-year rodent bioassays (Table 4) . It is important to emphasize that the hypothesis being tested by this type of validation is that these transgenic models will preferentially identify trans-species carcinogens and noncarcinogens. The TG.AC mouse line is responsive to a number of tumor promoters, but this is not a useful distinction in the context of the rodent bioassay. The principle of trans-species effects (17) should apply, since chemicals that can promote only in a single-species or strain are subject to the action of gene(s) or chemical specificity that limit their carcinogenic (or promotion) potential (67) . Thus, while the TG.AC mouse line may identify chemicals with the capacity to promote tumor development in a mouse two-stage assay, its use is aimed principally at the detection of nonmutagenic carcinogens, for the verification of mutagenic carcinogens positive in the p53 +/-mouse line and for dose-response data.
This strategy can also be applied to problems associated with the development of new products for commercial or medicinal uses. Widespread application of the Salmonella mutagen assay has resulted in a marked decrease in the development of new products or chemicals that are positive in that assay. However, approximately 30% of such chemicals have not been carcinogenic when tested in 2-year bioassays.
Because most mutagens are carcinogenic and because of the economic and regulatory risks (i.e., what information is needed to override a positive result in a Salmonella mutagenesis assay), the development of such products may be abandoned early. The use of the proposed predictive strategy outlined here can result in the identification of such "mutagenic noncarcinogens" and provide a scientific and economic justification for further development or for a more informed decision to conduct a costly bioassay to verify the lack of carcinogenic potential.
This strategy is not presented as a panacea to all of the public health issues associated with environmental carcinogens and risk assessment. It represents the use of new experimental tools to search for answers to such problems, and it can be objectively challenged and validated using ongoing and future bioassays. The strategy provides a mechanistic basis for judging the carcinogenicity of chemicals and for better defining the specific chemical-gene interactions that induce and promote the development of cancers.
